Search Within

Matthew J Matasar

Refine Results
Formats
  1. Meeting Abstract (75)
  2. Journal Article (40)
  3. Book Section (3)
  4. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (119)
  2. Hematologic Oncology, Division of (119)
  3. Lymphoma (119)
  4. Lymphoma Service (119)
  5. Population Sciences Research Program (119)
  6. Survivorship Research (119)

More Groups

People
  1. Craig Moskowitz (69)
  2. Andrew Zelenetz (52)
  3. David Straus (46)
  4. Paul Hamlin (45)
  5. Alison Moskowitz (44)
  6. Steven Horwitz (42)

More People

Years
  1. 2018 (14)
  2. 2017 (27)
  3. 2016 (17)
  4. 2015 (22)
  5. 2014 (12)
  6. 2013 (8)

More Years

Publications
  1. Blood (49)
  2. Journal of Clinical Oncology (14)
  3. Biology of Blood and Marrow Transplantation (10)
  4. Hematological Oncology (9)
  5. Annals of Oncology (3)
  6. British Journal of Haematology (3)

More Publications

Publishers
  1. American Society of Hematology (50)
  2. Elsevier Inc. (15)
  3. American Society of Clinical Oncology (14)
  4. Wiley Blackwell (11)
  5. Oxford University Press (7)
  6. John Wiley & Sons (3)

More Publishers

Results (119)

Export to EndNote | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors
    Journal Article

    Salz, T.; Zabor, E. C.; de Nully Brown, P.; Oksberg Dalton, S.; Raghunathan, N. J.; Matasar, M. J.; Steingart, R.; Vickers, A. J.; Munksgaard, P. S.; Oeffinger, K. C.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma
    Journal Article

    Thomas, A. A.; Abrey, L. E.; Terziev, R.; Raizer, J.; Martinez, N. L.; Forsyth, P.; Paleologos, N.; Matasar, M.; Sauter, C. S.; Moskowitz, C.; more...
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer
    Journal Article

    Chan, A. T.; Plodkowski, A. J.; Pun, S. C.; Lakhman, Y.; Halpenny, D. F.; Kim, J.; Goldburg, S. R.; Matasar, M. J.; Moskowitz, C. S.; Gupta, D.; more...
    Journal of Cardiovascular Magnetic Resonance (2017)

    Fulltext@MSK | Save
  • Communication between oncologists and lymphoma survivors during follow-up consultations: A qualitative analysis
    Journal Article

    Franco, K.; Shuk, E.; Philip, E.; Blanch-Hartigan, D.; Parker, P. A.; Matasar, M.; Horwitz, S.; Kissane, D.; Banerjee, S. C.; Bylund, C. L.
    Journal of Psychosocial Oncology (2017)

    Fulltext@MSK | Save
  • Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era treated at Memorial Sloan Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P.; Horwitz, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2017)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma: Updated results of a Phase 1b/2 study
    Meeting Abstract

    Matasar, M.; Herrera, A. F.; Kamdar, M.; Mehta, A.; Assouline, S.; Fleury, I.; Kim, T. M.; Kim, W. S.; Bosch, F.; Radford, J.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory FL or DLBCL: Updated result of a Phase 1b/2 study
    Meeting Abstract

    Matasar, M.; Herrera, A. F.; Kamdar, M.; Mehta, A.; Assouline, S.; Fleury, I.; Kim, T. M.; Kim, W. S.; Bosch, F.; Radford, J.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Whole-body diffusion-weighted MR imaging in lymphoma surveillance
    Meeting Abstract

    Rademaker, J.; Ryan, D.; Matasar, M.; Portlock, C.
    Hematological Oncology (2017)

    Fulltext@MSK | Save